The influence of drug kinetics in blood on the calculation of oral bioavailability in linear pharmacokinetics: The traditional equation may considerably overestimate the true value

Journal of Pharmaceutical Sciences

Volumn 95, Issue 4, 2006, Pages 834-848

  Berezhkovskiy, Leonid M ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Blood cell partitioning; Central drug elimination; Dissociation rate constant; Linear pharmacokinetics; Oral bioavailability calculation; Protein binding

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BLOOD CELL; CALCULATION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG ELIMINATION; LIPID BLOOD LEVEL; MATHEMATICAL COMPUTING; MODEL; PROTEIN BINDING; SYSTEMIC CIRCULATION;

EID: 33645960418     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20570     Document Type: Article

References (19)

1. Dost FH. 1968. Grundlagen den pharmacokinetic. Leipzig: G. Thieme.
2. Nüesch E. 1973. Proof of the general validity of Dost's law of corresponding areas. Eur J Clin Pharm 6:33-43.
3. Vaughan DP. 1977. A model independent proof of Dost's law of corresponding areas. J Pharmacokinet Biopharm 5:271-277.
4. Wagner JG. 1981. History of pharmacokinetics. Pharmacol Ther 12:537-562.
5. Korn GA, Korn TM. 1961. Mathematical handbook for scientists and engineers. New York: McGraw-Hill.
6. Oppenheimer JH, Schwartz HL, Surks MI. 1975. Determination of common parameter of iodothyronine metabolism and distribution in man by noncompartmental analysis. J Clin Edocrin Metab 41:319-324.
7. Benet LZ, Galeazzi RL. 1979. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68:1071-1074.
8. Berezhkovskiy LM. 2004. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci 93:364-374.
9. Berezhkovskiy LM. 2004. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:1628-1640.
10. Veng-Pedersen P, Gillespie WR. 1987. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concept applied to the evaluation of distribution kinetics. J Pharmacokinet Biopharm 15:281-304.
11. Freedman FB, Johnson JA. 1969. Equilibrium and kinetic properties of the Evan blue-albumin system. Am J Physiol 216:675-681.
12. Markgren P-O, Schaal W, Hamalainen M, Karlen A, Hallberg A, Samuelsson B, Danielson UH. 2002. Relationship between structure and interaction kinetics for HIV-1 protease inhibitors. J Med Chem 45:5430-5439.
13. Yuan J, Yang DC, Birkmeier J, Stolzenbach J. 1995. Determination of protein binding by in vitro charcoal adsorption. J Pharmacokinet Biopharm 23:41-55.
14. Pang KS, Rowland M. 1977. Hepatic clearance of drugs. I. Theoretical consideration of a "well-stirred" model and a "parallel tube" model. Influence of hepatic drug flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
15. Wilkinson GR, Shand DJ. 1975. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
16. Cheng H, Gillespie R. 1996. Volumes of distribution and mean residence time of drugs with linear tissue distribution and binding and nonlinear protein binding. J Pharmacokinet Biopharm 24:389-402.
17. Wagner JG. 1985. Effect of protein binding on steady-state equations. J Pharmacokinet Biopharm 13:559-560.
18. McNamara PJ, Gibaldi M, Stoeckel K. 1983. Volume of distribution for a drug (ceftrioxone) exhibiting concentration dependent protein binding. Eur J Clin Pharmacol 25:399-405.
19. Klabunde RE. 2004. Cardiovascular physiology concepts. Philadelphia: Lippincott Williams & Wilkins.